Combined Therapy of Nivolumab and Adoptive T Cell Therapy in Metastatic Melanoma Patients

Melanoma Clinical Trial

— Nivo-TIL  

Official title:

Combined Therapy of Nivolumab and Adoptive T Cell Therapy in Metastatic Melanoma Patients: Pilot Study Phase I/II

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03374839
• Other study ID #: RC15_0247
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: February 12, 2018
• Est. completion date: January 2024

Study information

• Verified date: May 2022
• Source: Nantes University Hospital
• Contact: Amir Khammari, PhD
• Phone: (+33) (0)2 40 08 32 80
• Email: amir.khammari[@]chu-nantes.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To improve the efficacy of immunotherapy for cancer, recent studies focused on specific targets to redirect the immune network toward eradicating a variety of tumors and ameliorating the self-destructive process.

A clinically relevant immune escape mechanism in melanoma is the activation of the Programmed cell Death-1 (PD-1) receptor on infiltrating T cells. By blocking PD-1 receptors with anti-PD-1 monoclonal antibodies (mAbs), T-cells are unaffected by the PD-L1 expressed on tumor cells and the patients T cells are free to respond to melanoma antigens and attack tumor cells. So the objective of this trial is to evaluate the safety and the efficacy of a combined therapy Nivolumab and adoptive T cell therapy in metastatic melanoma patients.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 11
• Est. completion date: January 2024
• Est. primary completion date: January 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• over 18 years old with a weight = 40 kg

• Patients must have signed informed consent

• Patients with stage IIIb, IIIc or IV metastatic melanoma (AJCC 6th edition) with at least two lesions (lymph nodes relapse, or in transit metastasis, or unresectable cutaneous metastases, or visceral metastases except bone and brain metastases) including one easily accessible and no more than 2 lines of treatment of melanoma at the metastatic stage.

• Patients with a melanoma expressing a Braf V600 mutation can be included

• Measurable/assessable disease in 28 days which precede the first administration of the treatment

• A negative pregnancy test for women with childbearing potential

• Eastern Cooperative Oncology Group (ECOG) of 0-1, Karnofsky > 80%

• Laboratory results:

Haemoglobin = 10 g/dl or = 6,25 mmol/l; Neutrophils = 1500/µl; Leukocytes = 4000/µl; Lymphocytes = 700/µl; Blood platelet = 100.000/µl; Serum creatinine = 1.5 x superior normal value or creatinine clearance (CrCl) = 40 mL/min (if using the Cockcroft-Gault formula); Serum bilirubin = 2.0 mg/dl or = 34.2 mol/l; Total bilirubin = 1.5 x superior normal value (except subjects with Gilbert Syndrome, who can have total bilirubin < 3mg/dL); Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) = 2 x superior normal value; Lactate dehydrogenase (LDH) = 1.5 x superior normal value

• Subjects affiliated to an appropriate health insurance

• Women of childbearing potential (WOCBP) must use appropriate method(s) of contraception during the clinical trial. Furthermore WOCBP will be instructed to adhere to contraception for a period of 5 months after the last dose of Nivolumab.

• Men who are sexually active with WOCBP will be instructed to adhere to contraception during the clinical trial and for a period of 7 months after the last dose of Nivolumab.

• Women who are not of childbearing potential (ie, who are postmenopausal or surgically sterile) as well as azoospermic men do not require contraception.

Non inclusion Criteria:

• Brain or bone metastases

• Ocular melanoma

• Chemotherapy or radiotherapy within 4 weeks before baseline (6 weeks for nitroso-ureas and mitomycin C)

• Contraindication for the use of vasopressor agents

• For female: the patient is pregnant or breastfeeding or not using contraception

• For men: the patient is sexually active with WOCBP and not using contraception

• History or current manifestations of severe progressive heart disease (congestive heart failure, coronary artery disease, uncontrolled arterial hypertension, serious rhythm disorders or ECG signs of previous myocardial infarction)

• Patients should be excluded if they have had prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA4 antibody, or any other antibody or drug specifically targeting T-cell costimulation or immune checkpoint pathways except in the context of adjuvant or neoadjuvant

• History of allergies and Adverse Drug Reaction:

• Hypersensitivity to human albumin, TIL excipient

• Hypersensitivity to Nivolumab or related excipients

• History of severe hypersensitivity reaction to any monoclonal antibody

• Hypersensitivity to aldesleukin or to one of Proleukin excipients

• History of chronic autoimmune disease (Addison's disease, multiple sclerosis, Graves' disease, rheumatoid arthritis, systemic lupus erythematosus, etc…) except patient with active vitiligo or a history of vitiligo.

• History of uveitis or melanoma-associated retinopathy

• History of inflammatory bowel disease, celiac disease, or other chronic gastrointestinal conditions associated with diarrhea.

• Presence of a second active cancer, with the exception of an in situ cervical cancer or a skin cancer different from the treated melanoma

• Unchecked thyroid dysfunction

• Any serious, acute or chronic illness id est active infection asking for antibiotics administration, coagulation's disorders, or any state asking for an unauthorized concomitant treatment described in this study

• Patients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days before study drug administration. Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease. Subjects are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption). Physiologic replacement doses of systemic corticosteroids are permitted, even if > 10 mg/day prednisone equivalents. A brief course of corticosteroids for prophylaxis (eg, contrast dye allergy) or for treatment of nonautoimmune conditions (eg, delayed-type hypersensitivity reaction caused by contact allergen) is permitted.

• Adults under a legal protection regime (guardianship, trusteeship, "sauvegarde de justice")

Exclusion Criteria:

• Positive viral serology for HIV (human immunodeficiency virus) 1/2, p24 Ag, HTLV1, HTLV2, B and C hepatitis or syphilis

Related Conditions & MeSH terms

• Melanoma

Intervention

Drug:
• TIL + IL-2 + Nivolumab
The patients will receive Nivolumab (at a dose of 3 mg per kilogram of body weight) every 2 weeks from day0 until week52. Two TIL (Tumor Infiltrating Lymphocytes) injections will be performed: at week 14 and at week 18. The TIL injections are systematically followed by subcutaneous injections of Proleukin® (IL-2) at a concentration of 6 million international unit (IU) per day for 5 days.

Locations

Country	Name	City	State
France	Nantes University Hospital	Nantes

Sponsors (2)

Lead Sponsor	Collaborator
Nantes University Hospital	Bristol-Myers Squibb

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of Treatment (adoptive T cell therapy associated to intravenous injections of Nivolumab) - Emergent Adverse Events	Clinical and biological criteria defined by the NCI (Common Terminology Criteria for Adverse Events - version 4.0, may 2009, http://ctep.cancer.gov)	Within 12 months
Secondary	Efficacy of adoptive T cell therapy associated to intravenous injections of Nivolumab	The overall tumor response will be evaluated according to the guidelines for Response Evaluation Criteria in Solid Tumors (RECIST1.1) and immune-related Response Criteria (irRC)	At 12 months
Secondary	Duration of the clinical response	Time interval between the evaluation of the first objective response and the first evaluation of disease progression or death, whichever occurs first	Within 12 months of follow-up
Secondary	Progression-free survival	Evaluation of the progression-free survival of patients treated with adoptive T cell therapy in combination with intravenous injections of Nivolumab	From the date of the first infusion of Nivolumab until the date of the first documented progression or the date of death from any cause, whichever came first, assessed up to 12 months
Secondary	Overall survival	Evaluation of the overall survival of patients treated with adoptive T cell therapy in combination with intravenous injections of Nivolumab	From the date of the first infusion of Nivolumab until the date of death, assessed up to 12 months
Secondary	Specific immune monitoring n°1: Evaluate the fraction of TIL specific to Melan-A and MELOE-1	Evaluation of the fraction of TIL specific to two Human Leukocyte Antigen (HLA)-peptide complexes (Melan-A and MELOE-1)	Week 14 + week 18
Secondary	Specific immune monitoring n°2: Evaluate the proportion of regulatory T cells	Evaluation of the proportion of regulatory T cells	Day 0 (1st Nivolumab injection) + week 14 + week 18 + week 26 + week 38 + at the date of disease progression assessed up to 12 months
Secondary	Specific immune monitoring n°3: Analyse the expression of tumor antigens	Analysis of the expression of tumor antigens	Week 10 + week 38
Secondary	Specific immune monitoring n°4: Analyse the expression of immunosuppressive cytokines	Analysis of the expression of immunosuppressive cytokines	Week 10 + week 38
Secondary	Specific immune monitoring n°5: Analyse the expression of indoleamine 2,3-dioxygenase (IDO)	Analysis of the expression of IDO	Week 10 + week 38
Secondary	Specific immune monitoring n°6: Analyse the expression of FoxP3	Analysis of the expression of FoxP3	Week 10 + week 38
Secondary	Specific immune monitoring n°7: Analyse the expression of regulatory molecules	Analysis of the expression of regulatory molecules	Week 10 + week 38
Secondary	Specific immune monitoring n°8: Analyse the mutations of BRAF	Analysis of BRAF mutations	Week 10 + week 38
Secondary	Specific immune monitoring n°9: Analyse the mutations of Neuroblastoma Ras viral oncogene homolog (NRAS)	Analysis of NRAS mutations	Week 10 + week 38
Secondary	Specific immune monitoring n°10: Analyse the mutations of proto-oncogene ckit (cKit)	Analysis of cKit mutations	Week 10 + week 38
Secondary	Specific immune monitoring n°11: Determine the percentage of reactive T cells in the expanded cells	Produce tumor cell line and determine the percentage of reactive T cells in the expanded cells	Week 10
Secondary	Specific immune monitoring n°12: Determine the phenotype of the expanded T cells	Produce tumor cell line and determine the phenotype of the expanded T cells	Week 10
Secondary	Specific immune monitoring n°13: Test TIL reactivity	Produce tumor cell line and test TIL reactivity	Week 10